51.68
0.98%
+0.50
After Hours:
51.15
-0.53
-1.03%
Incyte Corp. stock is currently priced at $51.68, with a 24-hour trading volume of 1.55M.
It has seen a +0.98% increased in the last 24 hours and a -8.61% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $51.13 pivot point. If it approaches the $51.90 resistance level, significant changes may occur.
Previous Close:
$51.18
Open:
$50.99
24h Volume:
1.55M
Market Cap:
$11.60B
Revenue:
$3.70B
Net Income/Loss:
$597.60M
P/E Ratio:
27.34
EPS:
1.89
Net Cash Flow:
$449.00M
1W Performance:
-1.28%
1M Performance:
-8.61%
6M Performance:
-4.77%
1Y Performance:
-29.72%
Incyte Corp. Stock (INCY) Company Profile
Name
Incyte Corp.
Sector
Industry
Phone
302-498-6700
Address
1801 Augustine Cut-Off, Wilmington, DE
Incyte Corp. Stock (INCY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
Jul-25-23 | Initiated | Citigroup | Buy |
May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
Jan-31-23 | Initiated | Piper Sandler | Overweight |
Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jan-07-21 | Initiated | Truist | Buy |
Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
Jun-16-20 | Initiated | The Benchmark Company | Hold |
May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-24-20 | Resumed | William Blair | Outperform |
Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Feb-04-20 | Resumed | BofA/Merrill | Neutral |
Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
Oct-03-19 | Initiated | Mizuho | Buy |
Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
May-21-19 | Initiated | Credit Suisse | Neutral |
May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
Apr-11-19 | Initiated | Stifel | Hold |
Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp. Stock (INCY) Latest News
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks Investment Research
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Zacks Investment Research
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Benzinga
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Benzinga
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
Incyte Corp. Stock (INCY) Financials Data
Incyte Corp. (INCY) Revenue 2024
INCY reported a revenue (TTM) of $3.70 billion for the quarter ending December 31, 2023, a +8.87% rise year-over-year.
Incyte Corp. (INCY) Net Income 2024
INCY net income (TTM) was $597.60 million for the quarter ending December 31, 2023, a +75.42% increase year-over-year.
Incyte Corp. (INCY) Cash Flow 2024
INCY recorded a free cash flow (TTM) of $449.00 million for the quarter ending December 31, 2023, a -49.67% decrease year-over-year.
Incyte Corp. (INCY) Earnings per Share 2024
INCY earnings per share (TTM) was $2.65 for the quarter ending December 31, 2023, a +74.34% growth year-over-year.
About Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Cap:
|
Volume (24h):